Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459227 | 0.75 | KDM1A (0.37) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL1458849 | 0.73 | TACR1 (0.35) | TACR1 | |
| SCHEMBL28574683 | 0.64 | KDM1A (0.50) | — | |
| SCHEMBL8747758 | 0.57 | PNMT (0.56) | OPRM1OPRL1 | |
| SCHEMBL22436648 | 0.57 | HTR1A (0.44) | — | |
| SCHEMBL15547924 | 0.57 | AKR1C1 (0.42) | MEN1MAPTKMT2AOPRM1OPRL1 | |
| SCHEMBL1458866 | 0.56 | CACNA1F (0.44) | DDB1CRBNMEN1KMT2AKCNH2 | |
| SCHEMBL1459225 | 0.56 | CACNA1F (0.41) | MEN1KMT2AKCNH2 | |
| SCHEMBL7587503 | 0.56 | HTR1A (0.46) | — | |
| SCHEMBL9295240 | 0.56 | KDM1A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011035355-A1 | NOVEL ANTIMALARIAL 3-AZABICYCLO[3.2.2]NONANE DERIVATIVES | UNIVERSITY OF GRAZ (AT) | 2011-03-31 | — | — | WO | disclosed |